Soleus Capital Management, L.P. Terns Pharmaceuticals, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.44 Billion
- Q4 2024
A detailed history of Soleus Capital Management, L.P. transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 8,142,500 shares of TERN stock, worth $27.3 Million. This represents 3.16% of its overall portfolio holdings.
Number of Shares
8,142,500
Previous 6,223,544
30.83%
Holding current value
$27.3 Million
Previous $51.9 Million
12.46%
% of portfolio
3.16%
Previous 4.41%
Shares
3 transactions
Others Institutions Holding TERN
# of Institutions
160Shares Held
83.9MCall Options Held
473KPut Options Held
119K-
Orbimed Advisors LLC San Diego, CA7.56MShares$25.3 Million1.14% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$23.1 Million7.51% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$18.7 Million1.37% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY4.75MShares$15.9 Million0.17% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$13.8 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $126M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...